 |
|
|
Andrew ZolopaAcademic Appointments
Appointment
Organization
Associate Professor - Med Center Line
|
Research Interests
Dr. Zolopa’s research applies a variety of clinical epidemiologic methods in an effort to optimize antiretroviral therapy and understand the impact of drug resistance on response to ARV. Areas of focus include the clinical application of resistance testing in optimizing antiretroviral therapy, clinical cohort and trials of antiretroviral therapies and population-based epidemiologic evaluation of HIV resistance and efficacy of ARV therapy in urban poor communities of San Francisco.
Publications
- Zolopa AR, "Incorporating Drug-Resistance Measurements into the Clinical Management of HIV-1 Infection." J Infect Dis 2006; 194 Suppl 1: S59-64 More »
- Liu M, Holodniy M, Zolopa AR, Shafer RW "Case Files From Stanford University Medical Center: The Initial Presentation of HIV-1 Infection -- Where Public and Personal Health Meet." MedGenMed 2006; 8: 1: 24 More »
- Mitsuya Y, Winters MA, Fessel WJ, Rhee SY, Hurley L, Horberg M, Schiffer CA, Zolopa AR, Shafer RW "N88D Facilitates the Co-occurrence of D30N and L90M and the Development of Multidrug Resistance in HIV Type 1 Protease following Nelfinavir Treatment Failure." AIDS Res Hum Retroviruses 2006; 22: 12: 1300-5 More »
- Zolopa AR, Lazzeroni LC, Rinehart A, Vezinet FB, Clavel F, Collier A, Conway B, Gulick RM, Holodniy M, Perno CF, Shafer RW, Richman DD, Wainberg MA, Kuritzkes DR "Accuracy, precision, and consistency of expert HIV type 1 genotype interpretation: an international comparison (The GUESS Study)." Clin Infect Dis 2005; 41: 1: 92-9 More »
- Rhee SY, Fessel WJ, Zolopa AR, Hurley L, Liu T, Taylor J, Nguyen DP, Slome S, Klein D, Horberg M, Flamm J, Follansbee S, Schapiro JM, Shafer RW "HIV-1 Protease and Reverse-Transcriptase Mutations: Correlations with Antiretroviral Therapy in Subtype B Isolates and Implications for Drug-Resistance Surveillance." J Infect Dis 2005; 192: 3: 456-65 More »
21 publications: view full list
